Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEM 3454 in mild to moderate Alzheimer's disease
NCT00454870Phase 2Completed
- Sponsor
- Memory Pharmaceuticals
- Start
- Feb 2007
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of facinicline in Alzheimer's disease (AD), sponsored by Memory Pharmaceuticals. Started Feb 2007; status: completed.
02
Drugs
facinicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00454870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00454870.